Log in using OpenID

Leishmaniasis Treatment Market 2026: Growth Recommendations By Experts

Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted through the bite of infected female phlebotomine sand flies.
Leishmaniasis Treatment Market Size, Share,
Trend, Outlook, Future Growth Analysis
And Synthesis By 2026
Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted
through the bite of infected female phlebotomine sand flies. According to the World Health Organization
(WHO), approximately 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur worldwide
annually due to the leishmaniasis. There are three forms of leishmaniasis namely mucocutaneous
leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis. Visceral leishmaniasis (VL) is the most
serious condition among the other two forms of leishmaniasis. According to the World Health
Organization (WHO), about 50,000 to 90,000 new cases of visceral leishmaniasis occur worldwide
Download PDF Brochure @
According to the WHO, in 2015, more than 90% of the new cases of visceral leishmaniasis were from
Kenya, Somalia, Ethiopia, India, Brazil, Sudan, and South Sudan creating higher opportunity for
leishmaniasis treatment market. The prevalence of cutaneous leishmaniasis in the North and South
America, the Middle East, Central Asia, and Mediterranean basin is approximately 95%, according to the
WHO April 2017 factsheet. People with leishmaniasis infection develop several symptoms, such as fever,
weight loss, sores on skin, nose, mouth or throat, enlargement of spleen and liver, and abnormal blood
tests. Some patients show symptoms of anemia, leukopenia, and thrombocytopenia. Geriatric population,
infants, pregnant or lactating women, and HIV infected people have a high risk of acquiring
leishmaniasis infections, due to their weak immune systems.
Introduction of new chemical entity will drive the leishmaniasis treatment market
According to data published in 2017, by Drugs for Neglected Diseases initiative (DNDi’), two new
chemical entities (NCE) DNDI-6148 and DNDI-0690 are introduced into the preclinical development stage
to treat visceral and cutaneous leishmaniasis in 2016. Immunomodulator- CpG-D35, is also in pre-clinical
development stage, which will be used as an adjunct along with drug therapy to fight cutaneous
leishmaniasis. These advances have the potential to transform drug development into new treatment
therapy in near future, in turn driving the growth of leishmaniasis treatment market.
Combined agreement between WHO and Gilead Sciences, Inc. will expand leishmaniasis treatment
In 2016, the World Health Organization (WHO) and Gilead Sciences, Inc. signed an agreement
to donate 3,80,400 vials of AmBisome (liposomal amphotericin B), extending their previous
agreement from 2016 to 2021. The five year collaboration and funding of US$ 20 million by
Gilead Sciences, Inc. are intended to provide access to diagnosis and treatment to the
populations affected by visceral leishmaniasis in key endemic countries such as Ethiopia, India,
Nepal, Bangladesh, South Sudan, and Sudan. Financial contribution made by Gilead Sciences,
Inc. helped WHO to expand, control, and reinforce surveillance in many endemic countries.
Report includes chapters which deeply display the following deliverable about industry :
• Leishmaniasis Treatment Market Research Objective and Assumption
• Leishmaniasis Treatment Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Leishmaniasis Treatment Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Leishmaniasis Treatment Market, By Regions
• Leishmaniasis Treatment Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Leishmaniasis Treatment Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Leishmaniasis Treatment Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Leishmaniasis Treatment Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key Players in the Leishmaniasis treatment market
Key players operating in the leishmaniasis treatment market include Sanofi S.A., Sequus Pharmaceuticals
Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, and Lifecare Innovations
Private Limited.
Leishmaniasis Treatment Market Taxonomy:
On the basis of disease type, the leishmaniasis treatment market is segmented into:
Cutaneous leishmaniasis
Visceral leishmaniasis
Mucocutaneous leishmaniasis
On the basis of drug type, the leishmaniasis treatment market is segmented into:
- Pentavalent antimonials
Sodium stibogluconate
SSG Meglumine antimoniate
- Antibiotics
Amphotericin B
Liposomal amphotericin B
Browse In-Depth Analysis Research Report @
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Poul Master
Poul Master217   documents Email
Health and Medicine
File Size
120 KB
treatment, Leishmaniasis Treatment Market
Report inappropriate content